Inactive Instrument

DiaMonTech AG

Biotechnology & Medical Research

DiaMonTech AG announced that it has received funding from Media Ventures GmbH

December 31, 2017

DiaMonTech AG announced that it has received funding from new investor Media Ventures GmbH in 2017.

Latest news about DiaMonTech AG

DiaMonTech AG announced that it has received funding from Moll Family GmbH, and other investors	07/12	CI
DiaMonTech AG announced that it has received $5 million in funding from IBB Beteiligungsgesellschaft mbH, Unorthodox Ventures, Samsung Venture Investment Corporation	17/22/17	CI
DiaMonTech AG has withdrawn its IPO in the amount of €59.375 million.	26/19/26	CI
DAK-Gesundheit and DiaMonTech AG Plan Strategic Cooperation in the Non-Invasive Blood Glucose Monitoring Sector for New Treatment Strategies in the Diabetes Sector	25/19/25	CI
DiaMonTech AG has filed an IPO in the amount of €59.375 million.	13/19/13	CI
DiaMonTech AG Signs A Further Agreement with an International Sales Company	11/19/11	CI
DiaMonTech GmbH Publishes Results of Clinical Study Confirming the Accuracy of its Non-Invasive Blood Glucose-Monitoring Technology	21/19/21	CI
DiaMonTech GmbH Appoints Enrico Just as Managing Director and CFO	01/19/01	CI
Deutscher Apothekerverband e. V. & DiaMonTech GmbH Intends Strategic Cooperation to Significantly Improve the Care of Diabetes Patients and to Take an Innovative Step into the Future	16/19/16	CI
DiaMonTech GmbH announced that it has received €7 million in funding from IBB Beteiligungsgesellschaft mbH, Bioventure Consulting GmbH, and other investors	09/19/09	CI
DiaMonTech GmbH announced that it has received funding from IBB Beteiligungsgesellschaft mbH, Macnica, Inc., Jindong Investment Group Co., Ltd.	05/18/05	CI
DiaMonTech AG announced that it has received funding from Media Ventures GmbH	31/17/31	CI

DiaMonTech AG is a Germany-based medical device company. It develops a device for non-invasive measuring of glucose levels in diabetes patients. The device is based on spectroscopy and uses photothermal detection technology. The device range under development includes a desktop device for clinical settings and multiple users, as well as a compact pocket device for the end user.

Sector

Biotechnology & Medical Research

More about the company